• CO2 concentrations in the atmosphere are at the highest of the modern record era
• EverGen develops and operates renewable natural gas projects that significantly reduce pollutants like CO2 and methane
• With major customers and partners, EverGen has expanded from a single facility in British Columbia to a series of projects across Canada

Natural gas prices are soaring around the world, partly contributing to the inflation in Europe that has risen to a record 10% in September. At the same time, citizens in New Jersey gripe over state regulators approving natural gas rate hikes that went into effect Saturday ahead of the cold weather season. While prices rise and all eyes are on natural gas, the climate change debate rages on. Throwing fuel into the fire, a special supplement to the bulletin of the American Meteorological Society that was released in August, paints an eye-popping picture of the level of carbon dioxide (“CO2”) in the atmosphere. Decarbonization isn’t easy, but thankfully, there are companies like EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) that are rising to the challenge to provide RNG solutions for utilities who are increasingly looking to reduce the world’s dependence on fossil fuels and slash pollution. According to the report, CO2 concentrations increased 2.6 parts per million in 2021 from 2020, the fifth-higher growth rate since the start of the instrumental record in 1958. The increase pushed CO2 concentration in the atmosphere to the highest of the modern record era and ice core records dating back 800,000 years. Not to be left out, methane (“CH4”) concentrations in 2021 were also at a record high. Methane comes from a variety of anthropogenic and natural sources, such as landfills, oil and natural gas systems, and agricultural activities, amongst other things. There are emerging technologies (i.e., low-carbon hydrogen, carbon capture, utilization, and storage) to neutralize the environmental effect of natural gas that will be available in the future. In the meantime, companies and utilities are increasingly turning to RNG, also called biogas, as an option to natural gas extracted from the Earth. RNG is produced from decomposing organic waste from landfills, agricultural waste, and wastewater from treatment facilities. The process includes using anaerobic (devoid of oxygen) digestors to break down waste to produce biogas and digestate. The biogas is purified and used for heat and electricity or as biomethane for the natural gas grid or for powering vehicles. Digestate puts to use captured nutrients like nitrogen and phosphorus, using it for products such as fertilizer and livestock bedding. Not only is the waste used productively for sustainable products, but usage as feedstock also prevents natural decomposition in landfills or storage ponds, meaning significant levels of methane are kept from being released into the atmosphere. Climate change awareness has consumers, regulators and companies alike clamoring about implementing sustainable alternatives to natural gas, driving demand for RNG. This benefits EverGen, which has contracts with utilities and municipalities to produce and sell its RNG. EverGen was initially focused within its home province of British Columbia, where it owns three projects – Fraser Valley Biogas, Net Zero Waste Abbottsford, and Sea to Sky Soils – before it began expanding eastward across the country. The company is amid an expansion at Fraser Valley Biogas that will double RNG production to ~160,000 gigajoules (“GJ”) per year as part of a longer-term strategy to reach 1,000,000 GJ. EverGen’s projects are all structured via long term offtake agreements, and they already have a buyer who has been eagerly looking for new RNG supply. As testament to this, last week, EverGen signed a term sheet for a long-term offtake agreement that would replace and expiring agreement for RNG production at Fraser Valley. Pursuant to the new terms, the buyer commits to purchasing up to 190,000 GJ annually from the facility. To the east, EverGen has a 67% stake in GrowTEC, a multi-faceted bioenergy venture located on the Perry Family farm outside Lethbridge, Alberta that includes and operating biogas facility. The facility is slated to be modified to produce RNG that will be sold to FortisBC and tied into the local pipeline network. FortisBC is bullish on RNG, using it as part of its initiative to make a minimum of 15% of its gas supply carbon neutral by 2030. Most recently, EverGen acquired a 50% interest in Project Radius, a late-development stage portfolio of three high-quality RNG projects that will serve as the foundation of EverGen’s portfolio in Ontario. This project will cement EverGen’s position in the populous province that has copious amounts of organic feedstock. Collectively, the RNG output at the projects is estimate at 1,700,000 GJ annually. For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• The concussion controversy surrounding Tua Tagovailoa has prompted both the NFL and the NFLPA to revisit the league’s concussion protocol in a move designed to enhance player safety
• In the wake of this controversy, Odyssey is emphasizing the potential value of its PRV-002 novel compound for the treatment of concussions and the benefit of the players
• According to a report published by Vox, there are approximately 0.41 concussions per NFL game in American football, with 9.3% of concussions involving the loss of consciousness and 2.4% resulting in hospitalizations
• With such cases, there is a need to revise the NFL’s concussion protocol and push for a treatment option that is effective in the treatment of this condition
• Odyssey is at the forefront of a possible pharmaceutical treatment option, as it advances its clinical trials, to potentially receive FDA approval

Odyssey Health (OTC: ODYY) is looking to push its PRV-002 novel compound for the treatment of concussions given the National Football League (“NFL”) and National Football League Players Association’s (“NFLPA”) joint announcement on changes to the league’s concussion protocol (https://ibn.fm/LOjTi). As a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care, Odyssey recognizes the severity of concussions, especially in the NFL. In addition, it acknowledges the ineffectiveness of current treatment options available for patients. The Tua Tagovailoa concussion controversy has prompted the NLF and the NFLPA to revisit the league’s concussion protocol, citing a dire need to “enhance player safety.” On September 25, Tagovailoa was checked for a concussion, but the neurotrauma consultant responsible for the check made “several mistakes” in his evaluation, according to multiple reports. The Dolphins quarterback sustained a hit in the Week 3 game, but the team reported that he passed concussion protocols. On Thursday, September 29, he suffered another injury following a similar tackle, leaving him with head and neck injuries, coupled with a confirmed concussion which resulted in a trip to the hospital. The injuries following the second incident raised significant concerns and backlash, with many arguing that Tagovailoa should not have played and was in danger of serious injury. This led to the launch of an investigation, which is still ongoing. It has so far led to the termination of the neurotrauma consultant who checked Tagovailoa on September 25. On September 28, Odyssey announced the completion of all cohorts for its Phase I Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) clinical trial for its PRV-002 novel compound for concussion treatment. The drug proved safe and well tolerated throughout the trial, paving the way for the next phase of its clinical trial (https://ibn.fm/1puyq). PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. While it is yet to receive approval from the United States Food and Drug Administration (“FDA”), this compound has shown significant potential in pre-clinical studies treating concussions, going above and beyond what current alternatives in the market offer. A 2020 report published by Vox noted that American football has approximately 0.41 concussions per NFL game. The study also pointed out that 9.3% of concussions involve loss of consciousness, and 2.4% result in hospitalizations (https://ibn.fm/DAFZE). With such cases, there is a need to revise the NFL’s concussion protocol to guarantee the safety of players. There is also an urgency to push for a treatment option that effectively treats the condition. Odyssey is at the forefront of pushing a novel treatment as it advances its clinical trials with the ultimate objective of receiving FDA approval. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Lexaria is a global innovator in drug delivery platforms developing DehydraTECH-CBD as a potential treatment for hypertension
• A 2022 study documented a decline in the percentage of patients receiving appropriate treatment intensification over the last ten years
• This decline has been attributed to, among other possible reasons, the side effects of antihypertensive drugs
• At the same time, only 24% of adults with hypertension have the condition under control, a statistic attributable to the medications’ troublesome side effects
• Lexaria’s investigations of its DehydraTECH-CBD have so far presented favorable safety and tolerability data, meaning its drug candidate could offer reprieve to millions looking for antihypertensive drugs with little or no side effects

A recent study published in the American Heart Association (“AHA”) journal Hypertension concluded that “appropriate treatment intensification for older adults with hypertension in the United States was suboptimal over the past decade” (https://ibn.fm/yplwP). The study results showed the percentage of patients receiving appropriate treatment intensification – described as the addition of an antihypertensive drug to the patient’s care for high blood pressure – had declined over the ten years across all the three blood pressure targets used. The study sampled adults aged 60 and older who visited their primary care provider and previously had been diagnosed with hypertension, with the researchers focusing on patients that had undergone appropriate antihypertensive intensification. Although the study did not discuss the reasons behind the decline, a recent article analyzing the findings (https://ibn.fm/tjFIr) highlighted several theories that the study’s senior author Dr. Kenneth Mukamal offered. Per Dr. Mukamal, the decline might have resulted from “doctors’ concerns that blood pressure-lowering drugs might cause older adults to fall, patients’ reluctance to add more medications that might have more side effects, [and the difficulty faced by] primary care providers to treat high blood pressure aggressively in a typical 15-minute visit.” Dr. Mukamal’s theories document an existing concern. According to the U.S. Center for Disease Control (“CDC”), only about 24% of adults with hypertension have the condition under control (https://ibn.fm/g3qjt). A commonly cited reason for this low statistic is that patients stop taking their medication largely because of troublesome side effects. Even so, a solution, which is being developed for patients with hypertension by drug delivery platforms innovator Lexaria Bioscience (NASDAQ: LEXX), may be on the horizon (https://ibn.fm/rUOYQ). Packaged in the form of enhanced cannabidiol (“CBD”), whose bioavailability properties have been improved by the company’s patented DehydraTECH(TM) drug delivery technology, the solution, known simply as DehydraTECH-CBD, may potentially address the low antihypertensive intensification as well as the relatively high prescription abandonment rates for hypertension drugs. DehydraTECH-CBD has so far undergone animal and human studies as part of preliminary investigations designed to provide crucial data that would back Lexaria’s pursuit of registration for Phase Ib clinical trials.  The preliminary research showed that DehydraTECH delivered 317% more CBD to the blood 30 minutes after ingestion, a remarkable improvement considering the oral bioavailability of CBD is estimated at 6% (https://ibn.fm/HYDPx). Further human studies showed that DehydraTECH-CBD resulted in a rapid and prolonged drop in blood pressure, reduced arterial stiffness, and attenuated pulmonary artery systolic pressure. Generally, the studies yielded compelling CBD safety and tolerability data that were further reinforced by the company’s fourth human study, HYPER-H21-4, whose dosing Lexaria completed this summer. (Studies are available at https://ibn.fm/3DuBG, https://ibn.fm/mF15O, and https://ibn.fm/TUMYz. “We are extremely pleased that dosing has been completed on time in this multiweek clinical study without any adverse events having occurred,” said Lexaria CEO Chris Bunka of the fourth human study. “Demonstrating a noteworthy safety and tolerability profile relative to conventional antihypertensive medications is one of Lexaria’s major goals with this program, and avoiding serious adverse events at clinically efficacious doses will be a primary requirement to achieve eventual regulatory marketing authorizations.” Although CBD is usually well tolerated, it could cause liver toxicity in the high therapeutic doses required to treat conditions such as epilepsy or hypertension. Currently, there is only one FDA-approved CBD therapeutic, branded Epidiolex, used to treat seizures at a maximum approved dose of up to 10 mg per kilogram of body weight, given twice a day. But Lexaria believes DehydraTECH’s ability to increase CBD’s bioavailability could reduce the dose prescribed to patients (https://ibn.fm/WcfHe). With an eye on potentially delivering the second-ever FDA-approved CBD drug, Lexaria is working with the FDA to commence registered clinical trials and is on course to file an Investigational New Drug (“IND”) application in late 2022 or early 2023. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

The GSMI Future Workforce Conference is being held on October 11-13, 2022, as a virtual event. It is a great networking opportunity designed for decision-makers, HR executives, strategy and data analytics experts, and talent acquisition professionals from diverse industries to connect and collaborate on a common platform. At the Future Workforce Conference, traders can network and connect with top executives and company heads looking for robust strategies and ideas for investing in digital, remote, and hybrid work teams in their organizations. The Future Workforce team curates tailored sponsorship experiences by integrating new processes, technologies, and strategies for evolving workplace concepts. Top reasons to attend:

• Meet the stalwarts of the industry, all under a single roof
• Design digital workplace strategies
• Learn the latest technologies, ideas and strategies to acquire and grow your talent pool
• Foster a sense of workplace culture where employee well-being holds priority
• Collaborate amongst teams for better productivity and the finest outcome
• Use data information to understand the needs and requirements of your workforce and take steps to offer them the requisite support

The Future Workforce Conference will showcase an impressive panel of speakers sharing ideas and discussing what changes are required for offering a better experience to the HR, workforce and employee teams. Our research team put together some interesting numbers for executives and company heads to study and analyze:

• When offered greater flexibility at the workplace, 54% of employees were ready to stitch their jobs
• Teleworkers showed 35-40% more productivity that their office colleagues
• Companies save about $11000 per year, with part-time per telecommunicators

The presiding faculty includes HR executives & analysts, business heads, and performance strategists from all over the globe sharing their unmatched experience and expertise. These industry dignitaries will engage with the audience, directly sharing their years of experience in their respective work areas. Professionals interested in attending the event should download and fill in the registration form available on the link below, and can share with their colleagues and company heads what sessions they will attend and other details. Attendees can leverage this wonderful event floor to learn fresh ideas, tips, and technologies of the future that are ready to change the shape of the evolving workforce in the emerging digital landscape. To learn more, please visit https://ibn.fm/8Vtj1.

• FuelPositive is a technology company developing an onsite, containerized, green ammonia production system that decarbonizes and decentralizes ammonia production
• With the world currently experiencing a fertilizer crisis, experts opine that the answer to the issue lies with the adoption of better agriculture practices rather than increased fertilizer production
• On its part, FuelPositive is working on a multi-pronged approach that eliminates not only the greenhouse emissions associated with the production of traditional (“grey”) but also the emissions linked to manure application
• The company is advocating for deep injection of green ammonia into the ground to prevent pollution of groundwater and waterbodies as is the case when manure is used

A recent article in Politico highlights a dire situation in the agricultural sector – a worldwide fertilizer crisis that has seen farmers in both developed and developing countries grappling with high fertilizer prices. The burden, however, is disproportionately higher for those in developing nations, who have less financial capacity and organization to purchase fertilizers than their European counterparts (https://ibn.fm/La85b). Although the prices were high before Russia invaded Ukraine, the situation has only worsened following the invasion, resulting in a 50% increase in the pre-invasion figures. Coupled with additional factors such as spikes in shipping costs and energy prices, EU sanctions against Russia – which is the top producer and exporter of nitrogen fertilizer, the second-largest producer of potassium, and the third-largest supplier of phosphorus fertilizer – as well as restrictions instituted by Moscow blocking fertilizer exports, this has only worsened the situation. According to the article, one of the net effects has been an upset of “the delicate balance between ensuring that farmers get paid well enough for their produce while food is affordable enough for consumers.” However, if the prices continue on an uptrend due to such additional factors as high energy prices in the EU, food prices are bound to increase as farmers seek to cover their costs. The high energy costs in Europe have also threatened fertilizer production, with producers such as Yara delivering 22% less fertilizer to farmers in the second quarter of calendar 2022. But as the article points out, the answer to the fertilizer crisis does not lie in increasing fertilizer production, especially given that overuse can cause environmental degradation by, among other things, upsetting fragile ecosystems. The solution, experts reckon, is to limit “the overuse of fertilizer by adopting more environmentally-friendly agricultural practices,” a cause that clean energy solutions provider and technology company FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is also championing. On its part, FuelPositive has taken a multi-pronged approach that aims to produce green ammonia and push for the adoption of sustainable agricultural practices that eliminate pollution. Today, about 80% of the ammonia produced globally through energy- and emissions-intensive processes, one of which is the Haber Bosch process, is used in agriculture as a key source of nitrogen for fertilizer. (Nitrogen is agriculture’s most vital nutrient, given that plants absorb more nitrogen than any other element.) With the United Nations having predicted that the global demand for nitrogen fertilizers will have grown by 6% between 2017 and 2022, a growth trend that is set to continue or even accelerate (https://ibn.fm/yWQwj), meeting the demand will require the production of more ammonia. However, traditional methods of generating the compound emit three metric tonnes of greenhouse gases for every tonne of grey ammonia produced, a cause of great concern amid ongoing extreme weather events brought by climate change. FuelPositive has, therefore, developed an on-farm, containerized, green ammonia production system that decarbonizes ammonia production by relying on renewable electricity to synthesize hydrogen and nitrogen from water and air, respectively, before combining the molecules in a converter to create green ammonia. The system also provides an additional advantage: it decentralizes green ammonia production. This frees farmers from supply chain dependencies that can increase their vulnerability to disruptive events such as wars or price hikes due to increasing shipping prices. Similarly, farmers do not have to rely on manufacturers whose ability to produce and export nitrogen fertilizer is at the whim of government directives, energy prices and catastrophic weather. The company is on track to be fully validated and ready to deliver the first demonstration system of its green ammonia technology to a farm in Manitoba in the fall of 2022 as part of a demonstration pilot project. Moreover, it is accepting pre-sale orders (https://ibn.fm/N2nvS). FuelPositive believes its green ammonia system will enable farmers to sufficiently produce nitrogen fertilizer and, ultimately, power their generators, grain drying systems, ICE vehicles, and other farm equipment. In addition, FuelPositive is advocating for the deep injection of green ammonia to solve the emissions problem associated with manure use. A byproduct of farm animals, manure contains ammonia and is sprayed on the ground to act as a natural source of nitrogen. But its use as a fertilizer is considered pollutive when not handled appropriately. For example, manure releases gaseous ammonia into the atmosphere when sprayed on the ground. Additionally, the manure can be moved by rain and runoff into waterways or leech into groundwater, increasing nitrate levels and subsequently impacting the water quality (https://ibn.fm/gybh9). “In comparison to using manure as fertilizer, deep injection of green ammonia eliminates the emissions associated with manure,” the company’s website reads (https://ibn.fm/FPN3D). For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• The growing environmental regulations are prompting companies to explore ways to meet ESG (Environmental, Social, and Governance) goals, but which can come at a hefty up-front cost, a significant disadvantage to small and medium enterprises
• Energy optimization solution provider Correlate, through its smart team of experts and evolving technologies, makes solutions extremely affordable to more companies, businesses, and real estate owners
• The company has positioned itself as a one-stop shop for those looking to explore renewable energy sources, reduce their carbon emissions, meet government regulations, and achieve their ESG goals, covering all aspects, including planning, financing, and execution

Environmental, Social, and Governance (“ESG”) goals are becoming more integral in corporate America, with many players looking to preserve precious resources and slash their carbon emissions. In addition, the growing number of environmental regulations in the country is prompting companies to re-align their operations and explore new ways to meet the current standards. This shift has triggered resource-intensive efforts, including electrifying older buildings and, according to Marta Schantz, the co-executive director of Urban Land Institute, looking for talent with the right analytics experience and skills (https://ibn.fm/sEqDe). These efforts come at a hefty up-front cost, a significant disadvantage to small and medium enterprises. However, Correlate Infrastructure Partners (OTCQB: CIPI), a driver of highly cost-effective solutions for energy use optimization, is looking to make such privileges more accessible to more companies, businesses, and real estate owners through its financing program that makes upgrades extremely affordable. “The quest for ESG talent has never been bigger,” noted Mr. Schantz. “Everyone wants to be doing more on climate, there’s not enough staff to do it, and no one person can be an expert on all the different aspects of ESG that needs to be covered,” he added. Since it was founded in 2015, Correlate has always recognized a glaring opportunity in the industry, especially in the wake of mounting environmental regulations and the call for companies to reduce their carbon emissions. Starting as a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions, Correlate managed to venture into the solar energy and electric vehicle (“EV”) infrastructure sectors. Its acquisition of Solar Site Design in 2021 allowed Correlate to improve on its customer acquisition and project development for the commercial solar industry, ultimately growing its market share and having the ability to cater to even bigger customers. Today, the company has positioned itself as a one-stop shop for companies and real estate owners looking to explore renewable energy projects, reduce their carbon emissions, meet government regulations and achieve their ESG goals. “Correlate Infrastructure Partners loves supporting ESG-focused businesses that are making a true difference in their industries and communities,” noted Todd Michaels, Correlate’s Chief Executive Officer (“CEO”), during the announcement of the final engineering, permitting, and interconnection work at Continental Envelope (https://ibn.fm/6oqjZ). Correlate, through the systems and infrastructure it has built over the years, can offer unique solutions specifically designed to solve current problems within the United States market. Covering everything from planning to financing and execution has given it a significant competitive edge while doing away with small companies’ need to actively pursue certain ESG investments, including talent with the right analytics experience and skills. Going forward, Correlate plans to make it increasingly simple for people to find the company and take advantage of its offerings. It is well conversant with the current legal space from an environmental standpoint and is well equipped to help companies achieve their ESG goals. It looks to achieve this through its ever-growing team of experts, as well as its evolving technologies. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Hurricane Ian is the latest reminder that 83% of all major power outages are weather related
• GeoSolar Technologies SmartGreen(TM) homes include rooftop solar panels, battery systems, geothermal loops and electric air pump, premium insulation and more
• Installing a SmartGreen(TM) system reduces emissions by 8 tons annually and can eliminate energy-related utility bills

Devastating weather events like Hurricane Ian regularly leave millions of people throughout the path of the storm without power. In fact, it weather is nearly always responsible for major power outages, the culprit in 83% between 2000 and 2021, according to Climate Central. This begs the question of what can be done to help develop resilience? An answer: renewable energy and all-home solutions like that of GeoSolar Technologies (“GST”). Research this year by Berkeley Lab evaluated models of power outages throughout the U.S. and the potential for rooftop solar panels combined with battery systems to handle critical power loads. While there are considerable variables across the country – some regions use power-gobbling electric resistance heaters rather than efficient heat pumps, for example – the researchers found that even modestly sized systems could power a home for days at a time. Addition support in the case for solar is being lent by the ZeMod Delaware program, where Energize Delaware is working with Beracah Homes and the Milford Housing Development Corp. to offer people modular, solar-powered homes at prices significantly lower than the state’s current median home price. Energize Delaware is a non-profit providing grants and low-interest loans to help the state’s residents install solar and complete upgrades to be more energy efficient. For its part, GeoSolar offers an end-to-end solution to build new homes or retrofit existing homes with leading energy-efficient technologies. The company’s SmartGreen(TM) Home harnesses the power of the sun and earth to electrify a home while significantly reducing the owner’s pollutive footprint. The Denver-based company estimates installation of it whole-home solution cuts CO2 emissions by 800 pounds each year with the added monetary perk of reducing or eliminating utility bills. A GeoSolar home includes installation of geothermal ground loops and heat pump, electric water heater, premium insulation to ensure the building shell keeps the interior temp in and outside temp out, roof-mounted solar panels, upgraded, high-efficiency windows, CERV 2 air purification system, LED lighting, and a Storz battery backup system. Other options include a solar-powered hot tub, EV charging station, electric appliance upgrades, Xeriscape Landscape and water harvesting, and advance whole home water filtration system. The result is a home that has an efficiency rating that ranks amongst the highest in the industry based upon the Home Energy Rating System (“HERS(R)”) Index. The company even helps with arranging financing and suggests on its website that the savings from the elimination of utility bills can cover the cost of the SmartGreen(TM) products. Considering that a typical carbon-powered home in the U.S. uses 12,146 kilowatt hours of electricity and produces 8 metric tons of CO2 emissions every year, investing in systems like SmartGreen(TM) can have a meaningful effect on climate change. GeoSolar says that if it can apply its integrated system to 120 million homes, buildings, and businesses in the U.S., carbon emissions would be slashed by a whopping 60 trillion tons. This goes without mentioning reducing the strain on an aging and overloaded electric grid and being able to weather storms when power typically might be lost. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• REZYFi, Inc. is a real estate-oriented mortgage company servicing the needs of both traditional and non-traditional consumers and businesses
• The company operates through its two subsidiaries, REZYFi Lending, which is now focused on cannabis commercial real estate lending, and ResMac, Inc., a traditional mortgage origination, correspondent, and servicing business
• REZYFi seeks to provide access to financial services to the cannabis industry, which is still largely underserved because large financial companies have continuously shied away due to the illegality of cannabis at the federal level
• The US cannabis industry is expected to generate $52.6 billion in sales by 2026, up from an estimated $33 billion in 2022, figures that make it possibly the largest underbanked industry in the country

As of May 2022, 19 states, the District of Columbia, and two US territories – Guam and the Northern Mariana Islands – had legalized the recreational use of marijuana among adults, according to the National Conference of State Legislatures (https://ibn.fm/SbcVu). But federally, the possession and use of cannabis are illegal, as per the Controlled Substances Act of 1970 (“CSA”). And as a Financial Times (“FT”) article reports, cannabis companies had long been caught in the gap between state and federal law. “With top US banks such as JPMorgan Chase (NYSE: JPM) and Wells Fargo (NYSE: WFC) and payment companies including Visa (NYSE: V) and Mastercard (NYSE: MA) adhering to federal law, they have opted out of serving cannabis companies,” the FT article reads (https://ibn.fm/FSpMX). This had long starved cannabis companies of the ability to transact electronically, take out loans, and make deposits. However, the situation is changing for the better thanks to financial services companies like REZYFi that have emerged to cater to the cannabis industry. A real estate-oriented loan origination and servicing company, serving the needs of both traditional and non-traditional consumers and businesses, REZYFi primarily targets licensed and permitted cannabis companies and owners of real estate who lease to cannabis companies. Specifically, the company works to “provide senior loan and project financings to state-licensed operators in the cannabis industry, secured by real estate” and/or other permitted assets. REZYFi, which is led by senior executives with hands-on grasp of and experience in the state-permitted cannabis sectors as well as real estate and mortgage sectors, understands the myriad challenges cannabis companies and property owners who lease to such companies face when looking for real estate or project financing. In fact, the FT article believes the cannabis market, whose combined US medical and recreational sales are expected to reach an estimated $52.6 billion by 2026, up from an estimated $33 billion by the end of 2022 (https://ibn.fm/EoXiY), “can make a credible claim of being the largest underbanked industry in the US.” As companies like REZYFi try to fill this vacuum, providing access to financial services that the cannabis industry desperately needs, some fund managers cited in the article believe that “companies targeting this problem are among the most compelling businesses in the industry from an investment standpoint.” Moreover, the investment value proposition is boosted even further by REZYFi’s expectation that the “limited access to the mainstream banking and non-bank financing industry [will] continue for the foreseeable future.” Licensed in 36 states and headquartered in Miami, Florida, REZYFi operates through its two subsidiaries: REZYFi Lending, which is now focused on cannabis commercial real estate lending, and ResMac, Inc., a traditional mortgage origination, correspondent, and servicing business. In addition to targeting the state-licensed cannabis companies, REZYFi also offers financial services to companies and individual homeowners looking for a variety of real estate-related first and additional mortgage-based financing and project-specific financings. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs
• With concussion representing a high unmet need as there is currently no FDA-approved drug, Odyssey is developing a drug formulation, PRV-002, to be administered to concussed patients; the drug candidate is currently undergoing clinical evaluation
• In a recent announcement, the company reported the successful completion of its Phase I clinical trial, which showed that the drug was safe and well tolerated
• Odyssey is looking to present the findings of the Phase I study to the FDA and is also preparing for the planned Phase II trial

A soft and squishy organ that can be deformed with a simple touch, the human brain is extremely sensitive. And although it is encased in a sturdy skull and surrounded by a cushioning fluid that collectively work to protect it from the external environment and forces that could easily wreak havoc, it is still vulnerable to extremities. In fact, blows, jolts, violent shaking, or rapid decelerations as a result of an accident, for example, can and do override these protections, leading to a mild form of brain injury called mTBI or concussion or mTBI, an area of interest for medical company Odyssey Health (OTC: ODYY). Concussion Effects After a concussion, and depending on the concussed individual, the brain undergoes changes triggered by, among others, mechanical damage to neuronal connections, chemical imbalance, and activation of inflammation-inducing immune cells (https://ibn.fm/L7YoI), which cause such harmful responses as swelling, inflammation, and oxidative stress. mTBI also decreases blood flow to the brain, restricting glucose from traveling to the cells. To the concussed patient, these changes manifest in the form of symptoms such as dizziness, blurry vision, nausea and vomiting, headache, confusion, and, in some cases, loss of consciousness (https://ibn.fm/b1RKt). While most of these symptoms resolve over the course of several weeks to a few months, concussions can cause long-term consequences. For one, a single concussion raises the risk of having another concussion, with the second being more severe (https://ibn.fm/XFZaE). Relatedly, repetitive concussions are associated with the increased likelihood of developing neurodegenerative conditions such as Parkinson’s and Alzheimer’s disease, as well as chronic traumatic encephalopathy (“CTE”) (https://ibn.fm/Zhf00). PRV-002 Drug-Device Combination With the concussion space representing a high unmet medical need, given there is currently no FDA-approved drug for the condition, Odyssey Health took the initiative to develop one, guided by the need to nip the harmful responses in the bud before they can trigger severe symptoms. The outcome was PRV-002, a fully synthetic, non-naturally occurring neurosteroid. The drug formulation is designed to be administered into the upper nasal cavity a few minutes after a concussion, using the company’s patent-pending intranasal delivery device for onward travel to the brain along the cranial nerve. This route of administration, coupled with the drug’s lipophilic characteristics, enables PRV-002 to cross the blood-brain barrier within five minutes and spread throughout the brain within 30 minutes, reversing the harmful responses. PRV-002 has been the subject of ongoing clinical trials as part of a drug development program that, so far, has included preclinical animal studies and a clinical study. Animal studies evidenced that PRV-002 rapidly eliminates swelling, oxidative stress, and inflammation (https://ibn.fm/7ewOr). Motivated and having fulfilled FDA requirements, Odyssey embarked on the clinical human trial stage, announcing early last Fall that it had begun enrolling subjects for a Phase I trial to treat concussion (https://ibn.fm/p7BjD). Successful Phase I Clinical Trial In a recent news release published September 28, Odyssey reported the successful completion of this Phase I clinical trial, noting that the drug was safe and well tolerated throughout the study period (https://ibn.fm/CnRYO). The trial, a double-blinded, randomized, and placebo-controlled study that comprised a total of 40 healthy human volunteers, was segmented into two stages: Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”). The SAD stage consisted of 24 participants who were separated into three different groups, known as cohorts, and received varying doses of the drug at a ratio of 3:1 with placebo. (The treatment groups were given a low, medium, or high-single dose of PRV-002.) The MAD portion of the trial was made up of 16 subjects, separated into two cohorts, each with eight members. Each subject received a single low or high dose for five consecutive days. The Safety Review Committee (“SRC”) then monitored the subjects after the dosing of each cohort was complete. No adverse events were noted as the drug was well-tolerated for all the cohorts. Vital signs, EKG readings, sleep patterns, and breathing functions were all normal throughout the study, while blood samples showed no alterations associated with the PRV-002 treatment. Moreover, pharmacokinetic analysis, which revealed significantly lower levels of PRV-002 in the blood than what would be expected with other routes of administration, suggested a greater delivery of the drug formulation to the brain. “After reviewing the data from each of the cohorts, I have strong confidence that it is safe to proceed to the next clinical trial phase where PRV-002 will be administered for ten consecutive days to subjects following concussion,” commented Dallas Hack, MD, member of the SRC. “Of particular note, the overall low levels of PRV-002 in the blood supports the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. Less systemic exposure with this targeted approach promotes patient safety.” Odyssey is currently communicating with the FDA to present the findings from the Phase I trial while simultaneously preparing for the planned Phase II trial. More specifically, the company is identifying the Phase II trial sites and is working with its medical advisors to create a study design. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Silo Pharma, Inc recently uplisted to the Nasdaq Capital Market, raising gross proceeds of $5 million
• The biopharmaceutical company has sought to merge traditional therapeutics and psychedelic research, entering into a series of joint ventures with leading medical universities to carry out research into the field
• Meanwhile, psychedelics are gaining increasing favour within the United States with Oregon set to begin allowing the supervised usage of psilocybin from 2023 onwards

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million dollars through the sale of one million shares of its common stock. Furthermore, the company revealed that it had granted a 45-day option to its underwriter to purchase up to an additional 150,000 shares of common stock to cover over-allotments, if any.  Following the offering and as of September 27, 2022, the company’s common stock listed on the Nasdaq Capital Market and commenced trading under the ticker symbol “SILO” (https://ibn.fm/mmEsK). Originally founded in 2010, Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Increasingly and over the past two decades, clinical research on psychedelics, most notably psilocybin and methylenedioxymethamphetamine (“MDMA”), has steadily progressed from pilot studies confirming safety and feasibility, through to early phase trials providing preliminary evidence of clinical efficacy. Silo Pharma has been an early pioneer of these research studies through its commitment to develop innovative solutions to address a variety of underserved conditions, many of which are being carried out in partnership with leading medical universities across the globe. In one such instance, Silo Pharma has looked to engage in a sponsored study with the Netherland’s Maastricht University, examining the effect on repeated low doses of ketamine and psilocybin on cognitive and emotional dysfunctions resulting from Parkinson’s disease. Separately, the company has also entered into agreements with the University of California San Francisco (“UCSF”) to determine the effects of psilocybin on inflammation; with the University of Maryland, Baltimore to explore a novel invention known as joint-homing peptides; as well as simultaneously signing an agreement with Columbia University, granting it an option to license a number of assets under development including a prophylactic treatment for stress-induced disorders and PTSD. Although the use of psychedelics has been prolific amongst indigenous populations around the world for hundreds of years, recent medical studies have increasingly shown that psilocybin – a naturally occurring psychedelic prodrug produced within various species of fungi, along with other psychedelics, could have beneficial effects for a variety of mental health related conditions. This movement was further reinforced in 2018, when the U.S. Food and Drug Administration labelled psilocybin a “breakthrough therapy” in treatment for severe depression, a designation the agency applies to drugs that in early trials demonstrate substantial improvement over existing treatments (https://ibn.fm/bX5PY). In 2020, Oregon voters approved a ballot measure which paved the way for the state to put in place a legislative framework which, starting in 2023, will enable patients to take psilocybin under supervision (https://ibn.fm/FurGl). Following on from Oregon’s pioneering actions, Texas, Utah, and Washington State have all set up task forces or funded research into the medical use of psilocybin. Meanwhile, Maryland has created a $1 million fund to study alternative treatments, including psychedelics, for PTSD or traumatic brain injury, and to pay for such treatments for veterans. With psilocybin and psychedelic-based therapeutic treatment increasingly gaining favour amongst the medical community and with a rising prevalence of depression and mental disorders within modern society, forecasts have now projected the psychedelic drugs market to swell to a value of $6.8 billion annual by 2027, representing a CAGR of 16.3% within the forecast period of 2020 to 2027 (https://ibn.fm/qMaaq). Through their recent NASDAQ uplist and various research and drug developmental initiatives, Silo Pharma have sought to position themselves at the forefront of the psychedelic revolution currently affecting the medical field. “After the exciting progress we have made over the last year, uplisting to the NASDAQ is the next strategic step for Silo Pharma. A NASDAQ listing should provide greater liquidity for our investors, attract institutional investors, increase the visibility of the company and raise our overall profile,” said Eric Weisblum, CEO of Silo Pharma. For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO